EPMA position paper in cancer: Current overview and future perspectives

EPMA Journal

Volumn 6, Issue 1, 2015, Pages

  Grech, Godfrey ^a   Zhan, Xianquan ^b   Yoo, Byong Chul ^c   Bubnov, Rostyslav ^d,e   Hagan, Suzanne ^f   Danesi, Romano ^g   Vittadini, Giorgio ^h   Desiderio, Dominic M ⁱ  

^a UNIVERSITY OF MALTA   (Malta)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c National Cancer Center   (South Korea)

^d Clinical Hospital 'Pheophania' of State Affairs Department   (Ukraine)

^e ZABOLOTNY INSTITUTE OF MICROBIOLOGY AND VIROLOGY   (Ukraine)

^f GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^g UNIVERSITY OF PISA   (Italy)

^h Bracco Imaging   (Italy)

ⁱ UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Biobank; Biomarker; Disease modeling; Expert recommendation; Individual profile; Multimodal diagnostics; Predictive preventive personalized medicine; Risk assessment; Screening; Standardization

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; DNA; ESTROGEN RECEPTOR; K RAS PROTEIN; KI 67 ANTIGEN; MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; METHYLTRANSFERASE; MICRORNA; PROGESTERONE RECEPTOR; PROTEIN KINASE; PROTEIN P21; PROTEIN P27; PROTEIN P53; PROTEOME; PYRUVIC ACID; SURVIVIN; TRANSCRIPTOME; TRICARBOXYLIC ACID;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SUSCEPTIBILITY; CANCER THERAPY; CITRIC ACID CYCLE; COLON CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DNA METHYLATION; EARLY DIAGNOSIS; ELASTOGRAPHY; ENZYME ACTIVITY; EXPERIMENTAL ANIMAL; GENDER; GENE DOSAGE; GENETIC ASSOCIATION; GENETIC DISORDER; GLIOMA; GLYCOLYSIS; HUMAN; HYPOPHYSIS TUMOR; IN VIVO STUDY; INFLAMMATION; INTESTINE FLORA; LIVER CANCER; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MATHEMATICAL MODEL; METABOLITE; METABOLOME; MICROSATELLITE INSTABILITY; MOLECULARLY TARGETED THERAPY; NANOTECHNOLOGY; NON COMMUNICABLE DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PAPILLOMAVIRUS INFECTION; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRECANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PUBLIC HEALTH; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; TREATMENT RESPONSE; TUMOR MODEL;

EID: 84927713156     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1186/s13167-015-0030-6     Document Type: Article

References (391)

1. Golubnitschaja O, Yeghiazaryan K, Costigliola V, Trog D, Braun M, Debald M, et al. Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon? EPMA J. 2013;4(1):6. doi: 10.1186/1878-5085-4-6.
2. Del Re M, Di Paolo A, van Schaik RH, Bocci G, Simi P, Falcone A, et al. Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine? EPMA J. 2010;1(3):495-502. doi: 10.1007/s13167-010-0041-2.
3. World Health Organisation. Global status report on noncommunicable diseases 2010. http://whqlibdoc.who.int/publications/2011/9789240686458_eng.pdf?ua=1. Accessed 18 Jan 2014.
4. Enserink M. After the windfall. Science. 2014;345(6202):1258-9. doi: 10.1126/science.345.6202.1258.
5. Parry CD, Patra J, Rehm J. Alcohol consumption and non-communicable diseases: epidemiology and policy implications. Addiction. 2011;106(10):1718-24. doi: 10.1111/j.1360-0443.2011.03605.x.
6. UN Declaration. http://www.un.org/en/ga/ncdmeeting2011/pdf/NCD_draft_political_declaration.pdf. Accessed 18 Jan 2014.
7. Love RR, Ginsburg OM, Coleman CN. Public health oncology: a framework for progress in low-and middle-income countries. Ann Oncol. 2012;23(12):3040-5. doi: 10.1093/annonc/mds473.
8. Coleman CN, Formenti SC, Williams TR, Petereit DG, Soo KC, Wong J, et al. The international cancer expert corps: a unique approach for sustainable cancer care in low and lower-middle income countries. Front. Oncol. 2014;4:333. doi: 10.3389/fonc.2014.00333.
9. Arnedos M, Soria JC, Andre F, Tursz T. Personalized treatments of cancer patients: a reality in daily practice, a costly dream or a shared vision of the future from the oncology community? Cancer Treat Rev. 2014;40(10):1192-8. doi: 10.1016/j.ctrv.2014.07.002.
10. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet. 1997;349(9063):1436-42.
11. Gulley ML, Morgan DR. Molecular oncology testing in resource-limited settings. J Mol Diagn. 2014;16(6):601-11. doi: 10.1016/j.jmoldx.2014.07.002.
12. Yunus M. Building social business: the new kind of capitalism that serves humanity's most pressing needs. New York: PublicAffairs; 2011.
13. Roy MJ, Donaldson C, Baker R, Kay A. Social enterprise: new pathways to health and well-being? J Public Health Policy. 2013;34(1):55-68. doi: 10.1057/jphp.2012.61.
14. Roy MJ, Donaldson C, Baker R, Kerr S. The potential of social enterprise to enhance health and well-being: A model and systematic review. Soc Sci Med. 2014;123:182-93. doi: 10.1016/j.socscimed.2014.07.031.
15. Beaglehole R, Bonita R, Magnusson R. Global cancer prevention: an important pathway to global health and development. Public Health. 2011;125(12):821-31. doi: 10.1016/j.puhe.2011.09.029.
16. Popat K, McQueen K, Feeley TW. The global burden of cancer. Best Pract Res Clin Anaesthesiol. 2013;27(4):399-408. doi: 10.1016/j.bpa.2013.10.010.
17. Fenech A, Grech G. Pharmacogenetics and personalized medicine: Does gender have a role? J Malta Coll Pharm Pract. 2014;20:7-10.
18. Bubnov RV, Tymoshok NO, Nechypurenko OO, Spivak MY. Pros and cons, prospects and gender differences of use of diclofenac on rat models. The capabilities of musculoskeletal ultrasound for experimental osteoarthritis in rats. J Musculoskelet Ultrasound. 2015;1 Suppl 1:5.
19. Schmidt R, Baumann F, Hanschmann H, Geissler F, Preiss R. Gender difference in ifosfamide metabolism by human liver microsomes. Eur J Drug Metab Pharmacokinet. 2001;26(3):193-200.
20. Murray M. Role of signalling systems in the effects of dietary factors on the expression of mammalian CYPs. Expert Opin Drug Metab Toxicol. 2007;3(2):185-96. doi: 10.1517/17425255.3.2.185.
21. Chen Y, Tang Y, Guo C, Wang J, Boral D, Nie D. Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. Biochem Pharmacol. 2012;83(8):1112-26. doi: 10.1016/j.bcp.2012.01.030.
22. Mann HJ. Drug-associated disease: cytochrome P450 interactions. Crit Care Clin. 2006;22(2):329-45. doi: 10.1016/j.ccc.2006.02.004.
23. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet. 2005;44(10):989-1008. doi: 10.2165/00003088-200544100-00001.
24. Tang W, Norlin M, Wikvall K. Regulation of human CYP27A1 by estrogens and androgens in HepG2 and prostate cells. Arch Biochem Biophys. 2007;462(1):13-20. doi: 10.1016/j.abb.2007.04.001.
25. Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet. 2005;44(1):33-60. doi: 10.2165/00003088-200544010-00002.
26. Kennedy M. Hormonal regulation of hepatic drug-metabolizing enzyme activity during adolescence. Clin Pharmacol Ther. 2008;84(6):662-73. doi: 10.1038/clpt.2008.202.
27. Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science. 2013;342(6162):1094-8. doi: 10.1126/science.1241908.
28. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62(3):676-89. doi: 10.1086/301749.
29. Lynch HT, Smyrk T, Lynch JF. Molecular genetics and clinical-pathology features of hereditary nonpolyposis colorectal carcinoma (Lynch syndrome): historical journey from pedigree anecdote to molecular genetic confirmation. Oncology. 1998;55(2):103-8.
30. Krapfenbauer K, Drucker E, Thurnher D. Identification of tumour-related proteins as potential screening markers by proteome analysis-protein profiles of human saliva as a predictive and prognostic tool. EPMA J. 2014;5(1):20.
31. Mouliere F, El Messaoudi S, Gongora C, Guedj AS, Robert B, Del Rio M, et al. Circulating cell-free DNA from colorectal cancer patients may reveal high KRAS or BRAF mutation load. Transl Oncol. 2013;6(3):319-28.
32. Boone JD, Erickson BK, Huh WK. New insights into cervical cancer screening. J Gynecol Oncol. 2012;23(4):282-7. doi: 10.3802/jgo.2012.23.4.282.
33. Bruni L, Barrionuevo-Rosas L, Albero G, Aldea M, Serrano B, Valencia S, et al. ICO Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Europe. Summary Report 2015-03-24. http://www.hpvcentre.net/statistics/reports/XEX.pdf Accessed 02 Jan 2015.
34. Williamson D, Nagappan R, Sirikonda R, Rahnama F, Thomas S, Lovell-Smith M, et al. Distribution of HPV genotypes in women with cervical cancer in Auckland, New Zealand, a review of 50 specimens between 2000-2006. Aust N Z J Obstet Gynaecol. 2011;51(1):67-70. doi: 10.1111/j.1479-828X.2010.01251.x.
35. Wang T, Chang P, Wang L, Yao Q, Guo W, Chen J, et al. The role of human papillomavirus infection in breast cancer. Med Oncol. 2012;29(1):48-55. doi: 10.1007/s12032-010-9812-9.
36. Lazarenko LM, Nikitina OE, Nikitin EV, Demchenko OM, Kovtonyuk GV, Ganova LO, et al. Development of biomarker panel to predict, prevent and create treatments tailored to the persons with human papillomavirus-induced cervical precancerous lesions. EPMA J. 2014;5(1):1. doi: 10.1186/1878-5085-5-1.
37. Hiraku Y, Tabata T, Ma N, Murata M, Ding X, Kawanishi S. Nitrative and oxidative DNA damage in cervical intraepithelial neoplasia associated with human papilloma virus infection. Cancer Sci. 2007;98(7):964-72. doi: 10.1111/j.1349-7006.2007.00497.x.
38. Cebioglu M, Schild HH, Golubnitschaja O. Cancer predisposition in diabetics: risk factors considered for predictive diagnostics and targeted preventive measures. EPMA J. 2010;1(1):130-7. doi: 10.1007/s13167-010-0015-4.
39. Giovannini C, Scazzocchio B, Vari R, Santangelo C, D'Archivio M, Masella R. Apoptosis in cancer and atherosclerosis: polyphenol activities. Ann Ist Super Sanita. 2007;43(4):406-16.
40. Ramos KS, Partridge CR. Atherosclerosis and cancer: flip sides of the neoplastic response in mammalian cells? Cardiovasc Toxicol. 2005;5(3):245-55.
41. Ross JS, Stagliano NE, Donovan MJ, Breitbart RE, Ginsburg GS. Atherosclerosis and cancer: common molecular pathways of disease development and progression. Ann N Y Acad Sci. 2001;947:271-92. discussion 92-3.
42. Lam V, Su J, Koprowski S, Hsu A, Tweddell JS, Rafiee P, et al. Intestinal microbiota determine severity of myocardial infarction in rats. FASEB J. 2012;26(4):1727-35. doi: 10.1096/fj.11-197921.
43. Tlaskalova-Hogenova H, Stepankova R, Kozakova H, Hudcovic T, Vannucci L, Tuckova L, et al. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germfree and gnotobiotic animal models of human diseases. Cell Mol Immunol. 2011;8(2):110-20 doi: 10.1038/cmi.2010.67.
44. Rafter J, Bennett M, Caderni G, Clune Y, Hughes R, Karlsson PC, et al. Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients. Am J Clin Nutr. 2007;85(2):488-96.
45. Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol. 2005;23(2):276-92. doi: 10.1200/JCO.2005.10.042.
46. McBride KA, Ballinger ML, Killick E, Kirk J, Tattersall MH, Eeles RA, et al. Li-Fraumeni syndrome: cancer risk assessment and clinical management. Nat Rev Clin Oncol. 2014;11:260-71. doi: 10.1038/nrclinonc.2014.41.
47. Hearle N, Schumacher V, Menko FH, Olschwang S, Boardman LA, Gille JJ, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res. 2006;12(10):3209-15. doi: 10.1158/1078-0432.CCR-06-0083.
48. Bonadona V, Bonaiti B, Olschwang S, Grandjouan S, Huiart L, Longy M, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011;305(22):2304-10. doi: 10.1001/jama.2011.743.
49. Francke U. Retinoblastoma and chromosome 13. Cytogenet Cell Genet. 1976;16(1-5):131-4.
50. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997;276(5311):404-7.
51. Gnarra JR, Duan DR, Weng Y, Humphrey JS, Chen DY, Lee S, et al. Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochim Biophys Acta. 1996;1242(3):201-10.
52. Hirshfield KM, Rebbeck TR, Levine AJ. Germline mutations and polymorphisms in the origins of cancers in women. J Oncol. 2010;2010:297671. doi: 10.1155/2010/297671.
53. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010;363(4):301-4.
54. Hagan S, Orr MC, Doyle B. Targeted therapies in colorectal cancer-an integrative view by PPPM. EPMA J. 2013;4(1):3. doi: 10.1186/1878-5085-4-3.
55. Edwards AM, Isserlin R, Bader GD, Frye SV, Willson TM, Frank HY. Too many roads not taken. Nature. 2011;470(7333):163-5.
56. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883-92.
57. De Castro DG, Clarke P, Al-Lazikani B, Workman P. Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin Pharmacol Ther. 2012;93(3):252-9.
58. Feero WG, Guttmacher AE, Feero WG, Guttmacher AE, Collins FS. Genomic medicine-an updated primer. N Engl J Med. 2010;362(21):2001-11.
59. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998;396(6712):643-9.
60. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-51.
61. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012;486(7403):400-4.
62. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3(6):415-28.
63. Halushka MK, Fan J-B, Bentley K, Hsie L, Shen N, Weder A, et al. Patterns of singlenucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nature Genet. 1999;22(3):239-47.
64. Altshuler D, Pollara VJ, Cowles CR, Van Etten WJ, Baldwin J, Linton L, et al. An SNP map of the human genome generated by reduced representation shotgun sequencing. Nature. 2000;407(6803):513-6.
65. Hacia JG, Fan JB, Ryder O, Jin L, Edgemon K, Ghandour G, et al. Determination of ancestral alleles for human single-nucleotide polymorphisms using high-density oligonucleotide arrays. Nature Genet. 1999;22:164-7.
66. Parsons R. Phosphatases and tumorigenesis. Curr Opin Oncol. 1998;10(1):88-91.
67. Takakura S, Kohno T, Shimizu K, Ohwada S, Okamoto A, Yokota J. Somatic mutations and genetic polymorphisms of the PPP1R3 gene in patients with several types of cancers. Oncogene. 2000;19:836-40.
68. Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson D, Helgason A, et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nature Genet. 2007;39(5):631-7.
69. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nature Genet. 2007;39(5):645-9.
70. Tomlinson I, Webb E, Carvajal-Carmona L, Broderick P, Kemp Z, Spain S, et al. A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24. 21. Nature Genet. 2007;39(8):984-8.
71. Tuupanen S, Turunen M, Lehtonen R, Hallikas O, Vanharanta S, Kivioja T, et al. The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nature Genet. 2009;41(8):885-90.
72. Carrillo-De Santa Pau E, Real FX, Valencia A. Bioinformatics analysis of pancreas cancer genome in high-throughput genomic technologies. In: Azmi AS, editor. Molecular Diagnostics and Treatment of Pancreatic Cancer: Systems and Network Biology Approaches. Amsterdam: Elsevier; 2014. p. 93.
73. Fachal L, Gómez-Caamaño A, Barnett GC, Peleteiro P, Carballo AM, Calvo-Crespo P, et al. A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24. 1. Nature Genet. 2014;46(8):891-4.
74. Roberts JD, Kunkel TA. Fidelity of a human cell DNA replication complex. Proc Natl Acad Sci U S A. 1988;85(19):7064-8.
75. Kane DP, Shcherbakova PV. A common cancer-associated DNA polymerase e mutation causes an exceptionally strong mutator phenotype, indicating fidelity defects distinct from loss of proofreading. Cancer Res. 2014;74(7):1895-901.
76. Choi M, Scholl UI, Ji W, Liu T, Tikhonova IR, Zumbo P, et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc Nat Acad Sci USA. 2009;106(45):19096-101.
77. Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature. 2008;456(7218):66-72.
78. Ellegren H. Microsatellites: simple sequences with complex evolution. Nature Rev Genet. 2004;5(6):435-45.
79. Kashi Y, King DG. Simple sequence repeats as advantageous mutators in evolution. Trends Genet. 2006;22(5):253-9.
80. Thibodeau S, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science. 1993;260(5109):816-9.
81. Jiricny J, Nyström-Lahti M. Mismatch repair defects in cancer. Curr Opin Genet Dev. 2000;10(2):157-61.
82. Aaltonen LA, Peltomäki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin JP, et al. Clues to the pathogenesis of familial colorectal cancer. Science. 1993;260:812-6.
83. Caldés T, Perez-Segura P, Tosar A, de la Hoya M, Diaz-Rubio E. Microsatellite instability correlates with negative expression of estrogen and progesterone receptors in Sporadic Breast Cancer. Teratogenesis, Carcinogenesis, and Mutagenesis. 2000;20:283-91.
84. Schneider A, Borgnat S, Lang H, Régine O, Lindner V, Kassem M, et al. Evaluation of microsatellite analysis in urine sediment for diagnosis of bladder cancer. Cancer Res. 2000;60:4617-22.
85. Feinberg AP. Cancer epigenetics takes center stage. Proc Nat Acad Sci USA. 2001;98:392-4.
86. Jones PA, Laird PW. Cancer-epigenetics comes of age. Nature Genet. 1999;21:163-7.
87. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002;16(1):6-21.
88. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349(21):2042-54.
89. Dobrovic A, Simpfendorfer D. Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res. 1997;57(16):3347-50.
90. Galm O, Herman JG, Baylin SB. The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev. 2006;20(1):1-13.
91. Bronner C, Baker S, Morrison P, Warren G, Smith L, Lescoe M, et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is. Nature. 1994;368(6468):258-61.
92. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Nat Acad Sci. 1994;91(21):9700-4.
93. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343(19):1350-4.
94. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer. 2004;4(4):296-307.
95. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995;270:467-70.
96. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857-66.
97. Datta YH, Adams PT, Drobyski WR, Ethier SP, Terry VH, Roth MS. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol. 1994;12(3):475-82.
98. Gerhard M, Juhl H, Kalthoff H, Schreiber HW, Wagener C, Neumaier M. Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J Clin Oncol. 1994;12(4):725-9.
99. Katz AE, de Vries GM, Begg MD, Raffo AJ, Cama C, O'Toole K, et al. Enhanced reverse transcriptase-polymerase chain reaction for prostate specific antigen as an indicator of true pathologic stage in patients with prostate cancer. Cancer. 1995;75(7):1642-8.
100. Lokody I. RNA dynamics: destabilizing mRNAs promotes metastasis. Nat Rev Cancer. 2014;14(9):578-9.
101. Taback B, Chan AD, Kuo CT, Bostick PJ, Wang HJ, Giuliano AE, et al. Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease. Cancer Res. 2001;15:8845-50.
102. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 2000;6(4):1322-7.
103. Pandolfi PP. Aberrant mRNA translation in cancer pathogenesis: an old concept revisited comes finally of age. Oncogene. 2004;23(18):3134-7.
104. Grech G, von Lindern M. The role of translation initiation regulation in haematopoiesis. Comp Funct Genomics. 2012;2012:576540. doi: 10.1155/2012/576540.
105. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol. 2005;6(5):376-85.
106. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol. 2009;10(2):126-39.
107. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010;11(9):597-610.
108. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215-33.
109. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834-8.
110. Garzon R, Pichiorri F, Palumbo T, Iuliano R, Cimmino A, Aqeilan R, et al. MicroRNA fingerprints during human megakaryocytopoiesis. Proc Nat Acad Sci USA. 2006;103(13):5078-83.
111. Ciafre S, Galardi S, Mangiola A, Ferracin M, Liu C-G, Sabatino G, et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun. 2005;334(4):1351-8.
112. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005;65(14):6029-33.
113. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 2005;435(7043):839-43.
114. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10(10):704-14.
115. Costa FF. Non-coding RNAs: meet thy masters. Bioessays. 2010;32(7):599-608.
116. Birney E, Stamatoyannopoulos JA, Dutta A, Guigó R, Gingeras TR, Margulies EH, et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 2007;447(7146):799-816.
117. Srinivas PR, Kramer BS, Srivastava S. Trends in biomarker research for cancer detection. Lancet Oncol. 2001;2:698-704.
118. Copeland RA. Protein methyltransferase inhibitors as personalized cancer therapeutics. Drug Discov Today Ther Strategies. 2012;9(2):e83-90.
119. Copeland RA, Solomon ME, Richon VM. Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009;8(9):724-32.
120. Copeland RA. Molecular pathways: protein methyltransferases in cancer. Clin Cancer Res. 2013;19(23):6344-50.
121. Hung M-C, Link W. Protein localization in disease and therapy. J Cell Sci. 2011;124(20):3381-92.
122. Taylor J, Lymboura M, Pace PE, A'hern RP, Desai AJ, Shousha S, et al. An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non-familial breast cancers. Int J Cancer. 1998;79(4):334-42.
123. Al-Mulla F, Abdulrahman M, Varadharaj G, Akhter N, Anim JT. BRCA1 gene expression in breast cancer: a correlative study between real-time RT-PCR and immunohistochemistry. J Histochem Cytochem. 2005;53(5):621-9.
124. Troudi W, Uhrhammer N, Romdhane KB, Sibille C, Mahfoudh W, Chouchane L, et al. Immunolocalization of BRCA1 protein in tumor breast tissue: prescreening of BRCA1 mutation in Tunisian patients with hereditary breast cancer? Eur J Histochem. 2009;51(3):219-26.
125. Rodriguez JA, Au WW, Henderson BR. Cytoplasmic mislocalization of BRCA1 caused by cancer-associated mutations in the BRCT domain. Exp Cell Res. 2004;293(1):14-21.
126. Elstrodt F, Hollestelle A, Nagel JH, Gorin M, Wasielewski M, Van Den Ouweland A, et al. BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res. 2006;66(1):41-5.
127. Henderson BR. The BRCA1 breast cancer suppressor: regulation of transport, dynamics, and function at multiple subcellular locations. Scientifica (Cairo). 2012;2012:796808.
128. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411(6835):355-65.
129. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103(2):211-25.
130. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005;315(3):971-9.
131. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129-39.
132. Zwick E, Bange J, Ullrich A. Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med. 2002;8(1):17-23.
133. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169-81.
134. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5(5):341-54.
135. Perrotti M. Understanding PSA, and prostate cancer risk assessment. N J Med. 2001;98:35-8.
136. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002;359:572-7.
137. Hardt P, Mazurek S, Toepler M, Schlierbach P, Bretzel R, Eigenbrodt E, et al. Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br J Cancer. 2004;91(5):980-4.
138. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol. 2005;15(4):300-8.
139. Domon B, Aebersold R. Mass spectrometry and protein analysis. Science. 2006;312:212-7.
140. Yates JR. Mass spectral analysis in proteomics. Ann Rev Biophys Biomol Struct. 2004;33:297-316.
141. Sreekumar A, Poisson L, Rajendiran T. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009;457:910-4.
142. Kaddurah-Daouk R, Kristal BS, Weinshilboum RM. Metabolomics: a global biochemical approach to drug response and disease. Ann Rev Pharmacol Toxicol. 2008;48:653-83.
143. Gogvadze V, Zhivotovsky B, Orrenius S. The Warburg effect and mitochondrial stability in cancer cells. Mol Aspects Med. 2010;31(1):60-74.
144. Zhang D, Tai LK, Wong LL, Chiu L-L, Sethi SK, Koay ES. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol Cell Proteomics. 2005;4(11):1686-96.
145. Catherino WH, Mayers CM, Mantzouris T, Armstrong AY, Linehan WM, Segars JH. Compensatory alterations in energy homeostasis characterized in uterine tumors from hereditary leiomyomatosis and renal cell cancer. Fertil Steril. 2007;88(4):1039-48.
146. Yang Y, Li C, Nie X. Metabonomic studies of human hepatocellular carcinoma using high-resolution magicangle spinning 1H NMR spectroscopy in conjunction with multivariate data analysis. J Proteome Res. 2007;6:2605-14.
147. Tate AR, Foxall PJ, Holmes E. Distinction between normal and renal cell carcinoma kidney cortical biopsy samples using pattern recognition of (1)H magic angle spinning (MAS) NMR spectra. NMR Biomed. 2000;13:64-71.
148. Sitter B, Bathen T, Hagen B. Cervical cancer tissue characterized by high-resolution magic angle spinning MR spectroscopy. Magma. 2004;16:174-81.
149. Gao H, Lu Q, Liu X. Application of H-1 NMR-based metabonomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis. Cancer Sci. 2009;100:782-5.
150. Qiu Y, Cai G, Su M. Serum metabolite profiling of human colorectal cancer using GCTOFMS and UPLCQTOFMS. J Proteome Res. 2009;8:4844-50.
151. Hirayama A, Kami K, Sugimoto M. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res. 2009;69:4918-25.
152. Tiziani S, Lopes V, Günther UL. Early stage diagnosis of oral cancer using 1H NMRbased metabolomics. Neoplasia. 2009;11:269-76.
153. Brière JJ, Favier J, Gimenez-Roqueplo AP, Rustin P. Tricarboxylic acid cycle dysfunction as a cause of human diseases and tumor formation. Am J Physiol Cell Physiol. 2006;291:C1114-C20.
154. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancerassociated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739-44.
155. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Nat Acad Sci USA. 2007;104(49):19345-50.
156. Roudier E, Perrin A. Considering the role of pyruvate in tumor cells during hypoxia. Biochimica et Biophysica Acta (BBA)-Reviews on. Cancer. 2009;1796(2):55-62.
157. Lehnhardt FG, Bock C, Röhn G, Ernestus RI, Hoehn M. Metabolic differences between primary and recurrent human brain tumors: a 1H NMR spectroscopic investigation. NMR Biomed. 2005;18(6):371-82.
158. Hazany S, Hesselink JR, Healy JF, Imbesi SG. Utilization of glutamate/creatine ratios for proton spectroscopic diagnosis of meningiomas. Neuroradiology. 2007;49:121-7.
159. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009;457(7231):910-4.
160. Irvine T, Scott M, Clark C. A small rise in CEA is sensitive for recurrence after surgery for colorectal cancer. Colorectal Dis. 2007;9(6):527-31.
161. Körner H, Söreide K, Stokkeland PJ, Söreide JA. Systematic follow-up after curative surgery for colorectal cancer in Norway: a population-based audit of effectiveness, costs, and compliance. J Gastrointest Surg. 2005;9(3):320-8.
162. Wang JY, Tang R, Chiang JM. Value of carcinoembryonic antigen in the management of colorectal cancer. Dis Colon Rectum. 1994;37(3):272-7.
163. Fleming RA, Milano G, Thyss A, Etienne M-C, Renée N, Schneider M, et al. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res. 1992;52(10):2899-902.
164. Meinsma R, Fernandez-Salguero P, Van Kuilenburg A, Van Gennip A, Gonzalez F. Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea. DNA Cell Biol. 1995;14(1):1-6.
165. Yen JL, McLeod HL. Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur J Cancer. 2007;43(6):1011-6.
166. Des Guetz G, Schischmanoff O, Nicolas P, Perret G-Y, Morere J-F, Uzzan B. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer. 2009;45(10):1890-6.
167. Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J, et al. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer. 2009;45(3):365-73.
168. Popat S, Hubner R, Houlston R. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23(3):609-18.
169. Zaanan A, Fléjou J-F, Emile J-F, Des GG, Cuilliere-Dartigues P, Malka D, et al. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy. Clin Cancer Res. 2011;17(23):7470-8.
170. Fakih M, Wong R. Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer. Curr Oncol. 2010;17 Suppl 1:S3.
171. Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N Engl J Med. 2009;361(1):98-9.
172. Van Cutsem E, Köhne C-H, Hitre E, Zaluski J, Chang Chien C-R, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408-17.
173. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27(5):663-71.
174. Douillard J-Y, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010: JCO.2009.27.4860.
175. Bos JL, Fearon ER, Hamilton SR, Verlaan-De Vries M, van Boom JH, van der Eb AJ, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature. 1987;327(6120):293-7.
176. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010;28(3):466-74.
177. Douillard J-Y, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369(11):1023-34.
178. Oliner KS, Douillard J-Y, Siena S, Tabernero J, Burkes RL, Barugel ME, et al. Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC). J Clin Oncol. 2013;31(Suppl):3511.
179. Bekaii-Saab T. Moving forward with expanding to an "All-RAS Mutational Analysis" in metastatic colorectal cancer: beyond KRAS mutations. J Nat Compr Canc Netw. 2014;12(2):299-300.
180. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26(35):5705-12.
181. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet. 2011;377(9783):2103-14.
182. Van Cutsem E, Köhne C-H, Láng I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29(15):2011-9.
183. Alberts S, Cervantes A, Van De Velde C. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol. 2002;14 Suppl 2:ii31-6.
184. Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-97.
185. Kim HK, Green JE. Predictive biomarker candidates for the response of gastric cancer to targeted and cytotoxic agents. Pharmacogenomics. 2014;15(3):375-84.
186. Lordick F, Luber B, Lorenzen S, Hegewisch-Becker S, Folprecht G, Wöll E, et al. Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer. 2010;102(3):500-5.
187. Pinto C, Di Fabio F, Siena S, Cascinu S, Llimpe FR, Ceccarelli C, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol. 2007;18(3):510-7.
188. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma. Cancer. 2010;116(18):4256-65.
189. Kim H, Choi I, Kim C, Kim H, Oshima A, Yamada Y, et al. Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy. Pharmacogenomics J. 2010;12(2):119-27.
190. Dowsett M, Goldhirsch A, Hayes DF, Senn H-J, Wood W, Viale G. International webbased consultation on priorities for translational breast cancer research. Breast Cancer Res. 2007;9(6):R81.
191. Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, Veronesi P, et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors a study of preoperative treatment. Clin Cancer Res. 2004;10(19):6622-8.
192. Ring A, Smith I, Ashley S, Fulford L, Lakhani S. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer. 2004;91(12):2012-7.
193. Dowsett M, Houghton J, Iden C, Salter J, Farndon J, A'hern R, et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol. 2006;17(5):818-26.
194. Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesisgenerating study. J Clin Oncol. 2005;23(30):7512-7.
195. Mass RD, Press MF, Anderson S, Cobleigh MA, Vogel CL, Dybdal N, et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer. 2005;6(3):240-6.
196. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-82.
197. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659-72.
198. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer Jr CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-84.
199. Jahanzeb M. Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin Breast Cancer. 2008;8(4):324-33.
200. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-92.
201. Pritchard KI, Gelmon K, Rayson D, Provencher L, Webster M, McLeod D, et al. Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement. Current Oncology. 2013;20(1):48.
202. Baselga J, Campone M, Piccart M, Burris III HA, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520-9.
203. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783-91.
204. Jones RL, Salter J, A'Hern R, Nerurkar A, Parton M, Reis-Filho JS, et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2009;116(1):53-68.
205. Smith ML, Seo YR. Sensitivity of cyclin E-overexpressing cells to cisplatin/taxol combinations. Anticancer Res. 1999;20(4):2537-9.
206. Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK, Fuqua SA. Low levels of estrogen receptor ß protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res. 2004;10(22):7490-9.
207. Skliris GP, Munot K, Bell SM, Carder PJ, Lane S, Horgan K, et al. Reduced expression of oestrogen receptor ß in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol. 2003;201(2):213-20.
208. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Nat Acad Sci USA. 2001;98(19):10869-74.
209. Sørlie T, Tibshirani R, Parker J, Hastie T, Marron J, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Nat Acad Sci USA. 2003;100(14):8418-23.
210. Sotiriou C, Neo S-Y, McShane LM, Korn EL, Long PM, Jazaeri A, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Nat Acad Sci USA. 2003;100(18):10393-8.
211. Brunelli M, Manfrin E, Martignoni G, Bersani S, Remo A, Reghellin D, et al. HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations impact on selecting patients for herceptin therapy. Am J Clin Pathol. 2008;129(6):907-11.
212. Duffy MJ. Biochemical markers in breast cancer: which ones are clinically useful? Clin Biochem. 2001;34(5):347-52.
213. Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TAnDEM study. J Clin Oncol. 2009;27(33):5529-37.
214. Arpino G, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev. 2008;29(2):217-33.
215. Johnston S, Pippen J, Pivot X, Lichinitser M, Sadeghi S, Dieras V, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009;27(33):5538-46.
216. D'Amico M, Thomas A, Massey M, Herndon I, James E, Moore M-B, et al. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Cardiovasc Surg. 1999;117(4):736-43.
217. Jin M, Inoue S, Umemura T, Moriya J, Arakawa M, Nagashima K, et al. Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. Lung Cancer. 2001;34(2):207-18.
218. Vischioni B, Van der Valk P, Span S, Kruyt F, Rodriguez J, Giaccone G. Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small-cell lung cancer. Ann Oncol. 2004;15(11):1654-60.
219. Uramoto H, Osaki T, Inoue M, Taga S, Takenoyama M, Hanagiri T, et al. Fas expression in non-small cell lung cancer: its prognostic effect in completely resected stage III patients. Eur J Cancer. 1999;35(10):1462-5.
220. Koomägi R, Volm M. Expression of FAS (CD95/APO-1) and FAS ligand in lung cancer, its prognostic and predictive relevance. Int J Cancer. 1999;84(3):239-43.
221. Nakatsuka S, Takakuwa T, Tomita Y, Hoshida Y, Nishiu M, Yamaguchi M, et al. Hypermethylation of death-associated protein (DAP) kinase CpG island is frequent not only in B-cell but also in T-and natural killer (NK)/T-cell malignancies. Cancer Sci. 2003;94(1):87-91.
222. Cox G, Louise Jones J, Andi A, Abrams KR, O'Byrne KJ. Bcl-2 is an independent prognostic factor and adds to a biological model for predicting outcome in operable nonsmall cell lung cancer. Lung Cancer. 2001;34(3):417-26.
223. Ohsaki Y, Toyoshima E, Fujiuchi S, Matsui H, Hirata S, Miyokawa N, et al. bcl-2 and p53 protein expression in non-small cell lung cancers: correlation with survival time. Clin Cancer Res. 1996;2(5):915-20.
224. Silvestrini R, Costa A, Lequaglie C, Mochen C, Veneroni S, Leutner M, et al. Bcl-2 protein and prognosis in patients with potentially curable non-small-cell lung cancer. Virchows Arch. 1998;432(5):441-4.
225. Gessner C, Liebers U, Kuhn H, Stiehl P, Witt C, Schauer J, et al. BAX and p16INK4A are independent positive prognostic markers for advanced tumour stage of nonsmall cell lung cancer. Eur Resp J. 2002;19(1):134-40.
226. Tsao M-S, Aviel-Ronen S, Ding K, Lau D, Liu N, Sakurada A, et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non-small-cell lung cancer. J Clin Oncol. 2007;25(33):5240-7.
227. Harpole DH, Herndon JE, Wolfe WG, Iglehart JD, Marks JR. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res. 1995;55(1):51-6.
228. Pastorino U, Andreola S, Tagliabue E, Pezzella F, Incarbone M, Sozzi G, et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol. 1997;15(8):2858-65.
229. Kwiatkowski DJ, Harpole D, Godleski J, Herndon J, Shieh D-B, Richards W, et al. Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. J Clin Oncol. 1998;16(7):2468-77.
230. Ishida H, Irie K, Itoh T, Furukawa T, Tokunaga O. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with ki-67 growth fraction. Cancer. 1997;80(6):1034-45.
231. Geradts J, Fong KM, Zimmerman PV, Maynard R, Minna JD. Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. Clin Cancer Res. 1999;5(4):791-800.
232. Xu H-J, Cagle PT, Hu S-X, Li J, Benedict WF. Altered retinoblastoma and p53 protein status in non-small cell carcinoma of the lung: potential synergistic effects on prognosis. Clin Cancer Res. 1996;2(7):1169-76.
233. Slebos RJ, Kibbelaar RE, Dalesio O, Kooistra A, Stam J, Meijer CJ, et al. K-RAS oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med. 1990;323(9):561-5.
234. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007;98(12):1817-24.
235. Miller VA, Riely GJ, Zakowski MF, Li AR, Patel JD, Heelan RT, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol. 2008;26(9):1472-8.
236. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol. 2004;22(5):777-84.
237. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380-8.
238. Kojima H, Shijubo N, Abe S. Thymidine phosphorylase and vascular endothelial growth factor in patients with Stage I lung adenocarcinoma. Cancer. 2002;94(4):1083-93.
239. Koukourakis M, Giatromanolaki A, O'Byrnel K, Comley M, Whitehouse R, Talbot D, et al. Platelet-derived endothelialcell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. Br J Cancer. 1997;75(4):477-81.
240. Chen JJ, Yao P-L, Yuan A, Hong T-M, Shun C-T, Kuo M-L, et al. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res. 2003;9(2):729-37.
241. Chen GG, Merchant JL, Lai P, Ho RL, Hu X, Okada M, et al. Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89. Am J Pathol. 2003;162(6):1823-9.
242. Hayashi H, Sugio K, Matsumata T, Adachi E, Takenaka K, Sugimachi K. The clinical significance of p53 gene mutation in hepatocellular carcinomas from Japan. Hepatology. 1995;22(6):1702-7.
243. Honda K, Sbisa E, Tullo A, Papeo P, Saccone C, Poole S, et al. p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. Br J Cancer. 1998;77(5):776.
244. Park NH, Chung Y-H, Youn KH, Song B-C, Yang SH, Kim JA, et al. Close correlation of p53 mutation to microvascular invasion in hepatocellular carcinoma. J Clin Gastroenterol. 2001;33(5):397-401.
245. Sugo H, Takamori S, Kojima K, Beppu T, Futagawa S. The significance of p53 mutations as an indicator of the biological behavior of recurrent hepatocellular carcinomas. Surg Today. 1999;29(9):849-55.
246. Hu TH, Huang CC, Lin PR, Chang HW, Ger LP, Lin YW, et al. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer. 2003;97(8):1929-40.
247. Rahman MA, Kyriazanos ID, Ono T, Yamanoi A, Kohno H, Tsuchiya M, et al. Impact of PTEN expression on the outcome of hepatitis C virus-positive cirrhotic hepatocellular carcinoma patients: Possible relationship with COX II and inducible nitric oxide synthase. Int J Cancer. 2002;100(2):152-7.
248. Tavian D, De Petro G, Benetti A, Portolani N, Giulini SM, Barlati S. u-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma. Int J Cancer. 2000;87(5):644-9.
249. Ueki T, Fujimoto J, Suzuki T, Yamamoto H, Okamoto E. Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma. Hepatology. 1997;25(4):862-6.
250. Cui J, Dong B-W, Liang P, Yu X-L, Yu D-J. Construction and clinical significance of a predictive system for prognosis of hepatocellular carcinoma. World J Gastroenterol. 2005;11(20):3027-33.
251. He H, Wu G, Li W, Cao Y, Liu Y. CIP2A is highly expressed in hepatocellular carcinoma and predicts poor prognosis. Diagn Mol Pathol. 2012;21(3):143-9.
252. Watanabe J, Kushihata F, Honda K, Sugita A, Tateishi N, Mominoki K, et al. Prognostic significance of Bcl-xL in human hepatocellular carcinoma. Surgery. 2004;135(6):604-12.
253. Garcia EJ, Lawson D, Cotsonis G, Cohen C. Hepatocellular carcinoma and markers of apoptosis (bcl-2, bax, bcl-x): prognostic significance. Appl Immunohistochem Mol Morphol. 2002;10(3):210-7.
254. Ikeguchi M, Ueda T, Sakatani T, Hirooka Y, Kaibara N. Expression of survivin messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma. Diagn Mol Pathol. 2002;11(1):33-40.
255. Ikeguchi M, Ueta T, Yamane Y, Hirooka Y, Kaibara N. Inducible nitric oxide synthase and survivin messenger RNA expression in hepatocellular carcinoma. Clin Cancer Res. 2002;8(10):3131-6.
256. Ikeguchi M, Hirooka Y, Kaibara N. Quantitative analysis of apoptosis-related gene expression in hepatocellular carcinoma. Cancer. 2002;95(9):1938-45.
257. Ren Y, Poon RT-P, Tsui H-T, Chen W-H, Li Z, Lau C, et al. Interleukin-8 serum levels in patients with hepatocellular carcinoma correlations with clinicopathological features and prognosis. Clin Cancer Res. 2003;9(16):5996-6001.
258. Okumoto K, Hattori E, Tamura K, Kiso S, Watanabe H, Saito K, et al. Possible contribution of circulating transforming growth factor-beta1 to immunity and prognosis in unresectable hepatocellular carcinoma. Liver Int. 2004;24(1):21-8.
259. Tsai JF, Jeng JE, Chuang LY, Yang ML, Ho MS, Chang WY, et al. Elevated urinary transforming growth factor-beta1 level as a tumour marker and predictor of poor survival in cirrhotic hepatocellular carcinoma. Br J Cancer. 1997;76(2):244-50.
260. Verkaik NS, van Steenbrugge GJ, van Weerden WM, Bussemakers MJ, van der Kwast TH. Silencing of CD44 expression in prostate cancer by hypermethylation of the CD44 promoter region. Lab Invest. 2000;80(8):1291-8.
261. Seidman H, Mushinski MH, Gelb SK, Silverberg E. Probabilities of eventually developing or dying of cancer-United States, 1985. CA Cancer J Clin. 1985;35(1):36-56.
262. Cookson MS. Prostate cancer: screening and early detection. Cancer Control. 2001;8(2):133-40.
263. Lu-Yao G, Greenberg E. Changes in prostate cancer incidence and treatment in USA. The Lancet. 1994;343(8892):251-4.
264. Mettlin CJ, Murphy GP, Ho R, Menck HR. The National Cancer Data Base report on longitudinal observations on prostate cancer. Cancer. 1996;77(10):2162-6.
265. Tarone RE, Chu KC, Brawley OW. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology. 2000;11(2):167-70.
266. Alers JC, Rochat J, Krijtenburg P-J, Hop WC, Kranse R, Rosenberg C, et al. Identification of genetic markers for prostatic cancer progression. Lab Invest. 2000;80(6):931-42.
267. Amanatullah DF, Reutens AT, Zafonte BT, Fu M, Mani S, Pestell RG. Cell-cycle dysregulation and the molecular mechanisms of prostate cancer. Front Biosci. 2000;5:D372-D90.
268. Bostwick DG, Grignon DJ, Hammond MEH, Amin MB, Cohen M, Crawford D, et al. Prognostic factors in prostate cancer: College of American Pathologists consensus statement 1999. Arch Pathol Lab Med. 2000;124(7):995-1000.
269. Catalona WJ, Ramos CG, Carvalhal GF. Contemporary results of anatomic radical prostatectomy. CA Cancer J Clin. 1999;49(5):282-96.
270. Christiano AP, Yoshida BA, Dubauskas Z, Sokoloff M, Rinker-Schaeffer CW. Development of markers of prostate cancer metastasis: review and perspective. Urol Oncol. 2000;5(5):217-23.
271. Harding MA, Theodorescu D. Prostate tumor progression and prognosis: interplay of tumor and host factors. Urol Oncol. 2000;5(6):258-64.
272. Montironi R, Mazzucchelli R, Marshall JR, Bartels PH. Prostate cancer prevention: review of target populations, pathological biomarkers, and chemopreventive agents. J Clin Pathol. 1999;52(11):793-803.
273. Cheng L, Lloyd RV, Weaver AL, Pisansky TM, Cheville JC, Ramnani DM, et al. The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy. Clin Cancer Res. 2000;6(5):1896-9.
274. Halvorsen OJ, Haukaas SA, Akslen LA. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin Cancer Res. 2003;9(4):1474-9.
275. Kuczyk M, Machtens S, Hradil K, Schubach J, Christian W, Knüchel R, et al. Predictive value of decreased p27Kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients. Br J Cancer. 1999;81(6):1052-8.
276. Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J. deKernion JB, et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol. 1998;159(3):941-5.
277. Fosså A, Lilleby W, Fosså SD, Gaudernack G, Torlakovic G, Berner A. Independent prognostic significance of HER-2 oncoprotein expression in pN0 prostate cancer undergoing curative radiotherapy. Int J Cancer. 2002;99(1):100-5.
278. Osman I, Scher HI, Drobnjak M, Verbel D, Morris M, Agus D, et al. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res. 2001;7(9):2643-7.
279. Sanchez KM, Sweeney CJ, Mass R, Koch MO, Eckert GJ, Geary WA, et al. Evaluation of HER-2/neu expression in prostatic adenocarcinoma. Cancer. 2002;95(8):1650-5.
280. Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Nat Cancer Inst. 2000;92(23):1918-25.
281. Isaacs JT. Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer. Am J Pathol. 1997;150(5):1511.
282. Wikström P, Bergh A, Damber JE. Transforming growth factor-beta1 and prostate cancer. Scand J Urol Nephrol. 2000;34(2):85-94.
283. Borre M, Nerstrøm B, Overgaard J. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrinedifferentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin Cancer Res. 2000;6(5):1882-90.
284. van Brussel JP, Mickisch GH. Multidrug resistance in prostate cancer. Onkologie. 2003;26(2):175-81.
285. Borre M, Stausbøl-Grøn B, Nerstrøm B, Overgaard J. Immunohistochemical BCL-2 and Ki-67 expression predict survival in prostate cancer patients followed expectantly. Prostate Cancer Prostatic Dis. 1998;1(5):268-75.
286. Pollack A, Cowen D, Troncoso P, Zagars GK, von Eschenbach AC, Meistrich ML, et al. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma. Cancer. 2003;97(7):1630-8.
287. Adams J. Development of the proteasome inhibitor PS-341. The oncologist. 2002;7(1):9-16.
288. Lessard L. Mes-Masson AM, Lamarre L, Wall L, Lattouf JB, Saad F. NF-κB nuclear localization and its prognostic significance in prostate cancer. BJU international. 2003;91(4):417-20.
289. Elliott PJ, Ross JS. The proteasome a new target for novel drug therapies. Am J Clin Pathol. 2001;116(5):637-46.
290. Gilbertson RJ. Medulloblastoma: signalling a change in treatment. Lancet Oncol. 2004;5(4):209-18.
291. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Nat Cancer Inst. 1998;90(19):1473-9.
292. Bauman G, Ino Y, Ueki K, Zlatescu M, Fisher B, Macdonald D, et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Physics. 2000;48(3):825-30.
293. Brandes AA, Tosoni A, Cavallo G, Reni M, Franceschi E, Bonaldi L, et al. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol. 2006;24(29):4746-53.
294. Kouwenhoven M, Kros JM, French PJ, Biemond-ter Stege EM, Graveland WJ, Taphoorn MJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. Eur J Cancer. 2006;42(15):2499-503.
295. Silber JR, Bobola MS, Ghatan S, Blank A, Kolstoe DD, Berger MS. O6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics. Cancer Res. 1998;58(5):1068-73.
296. Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003.
297. Brandes AA, Franceschi E, Tosoni A, Bartolini S, Bacci A, Agati R, et al. O6-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. Neuro Oncol. 2010;12(3):283-8.
298. Riemenschneider MJ, Hegi ME, Reifenberger G. MGMT promoter methylation in malignant gliomas. Target Oncol. 2010;5(3):161-5.
299. Bleau A-M, Huse JT, Holland EC. The ABCG2 resistance network of glioblastoma. Cell Cycle. 2009;8(18):2936-44.
300. Wick W, Platten M, Weller M. New (alternative) temozolomide regimens for the treatment of glioma. Neuro Oncol. 2009;11(1):69-79.
301. Jeuken J, Sijben A, Alenda C, Rijntjes J, Dekkers M, Boots-Sprenger S. Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics. Brain Pathol. 2009;19(4):661-71.
302. Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Nat Cancer Inst. 2001;93(16):1246-56.
303. Sulis ML, Parsons R. PTEN: from pathology to biology. Trends Cell Biol. 2003;13(9):478-83.
304. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-73.
305. Parsons DW, Jones S, Zhang X, Lin JC-H, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807-12.
306. Weinstein B. Relevance of the concept of oncogene addiction to hormonal carcinogenesis and molecular targeting in cancer prevention and therapy. Adv Exp Med Biol. 2008;617:3-13. doi: 10.1007/978-0-387-69080-3_1.
307. McDonagh EM, Whirl-Carrillo M, Garten Y, Altman RB, Klein TE. From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. Biomark Med. 2011;5(6):795-806. doi: 10.2217/bmm.11.94.
308. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther. 2011;89(3):464-7. doi: 10.1038/clpt.2010.279.
309. Georgitsi M, Viennas E, Antoniou DI, Gkantouna V, van Baal S, Petricoin 3rd EF, et al. FINDbase: a worldwide database for genetic variation allele frequencies updated. Nucleic Acids Res. 2011;39(Database issue):D926-32. doi: 10.1093/nar/gkq1236.
310. Berliner L, Lemke HU. vanSonnenberg E, Ashamalla H, Mattes MD, Dosik D, et al. Model-guided therapy for hepatocellular carcinoma: a role for information technology in predictive, preventive and personalized medicine. EPMA J. 2014;5(1):16. doi: 10.1186/1878-5085-5-16.
311. Lemke HU, Golubnitschaja O. Towards personal health care with model-guided medicine: long-term PPPM-related strategies and realisation opportunities within 'Horizon 2020'. EPMA J. 2014;5(1):8. doi: 10.1186/1878-5085-5-8.
312. Bubnov RV, Melnyk IM. The methods of fractal analysis of diagnostic images. initial clinical experience. Lik Sprava. 2011;3-4:108-13.
313. Bubnov RV, Melnyk IM. Hepatic oncology diagnosis based on imaging fractal analysis. Preliminary results. EPMA J. 2014;5 Suppl 1:A43.
314. Davies RJ, Miller R, Coleman N. Colorectal cancer screening: prospects for molecular stool analysis. Nat Rev Cancer. 2005;5(3):199-209.
315. Graser A, Stieber P, Nagel D, Schaefer C, Horst D, Becker CR, et al. Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population. Gut. 2009;58(2):241-8.
316. Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: A Joint Guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008;58(3):130-60.
317. Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem. 2001;47(4):624-30.
318. Asiago VM, Alvarado LZ, Shanaiah N, Gowda GN, Owusu-Sarfo K, Ballas RA, et al. Early detection of recurrent breast cancer using metabolite profiling. Cancer Res. 2010;70(21):8309-18.
319. Chen T, Xie G, Wang X, Fan J, Qiu Y, Zheng X, et al. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol Cell Proteomics. 2011;10(7):M110. 004945.
320. Lee JH, Kim KH, Park JW, Chang HJ, Kim BC, Kim SY, et al. Low-mass-ion discriminant equation: a new concept for colorectal cancer screening. Int J Cancer. 2014;134(8):1844-53.
321. Yoo BC, Kong S-Y, Jang S-G, Kim K-H, Ahn S-A, Park W-S, et al. Identification of hypoxanthine as a urine marker for non-Hodgkin lymphoma by low-mass-ion profiling. BMC Cancer. 2010;10(1):55.
322. Kelly AD, Breitkopf SB, Yuan M, Goldsmith J, Spentzos D, Asara JM. Metabolomic profiling from formalin-fixed, paraffin-embedded tumor tissue using targeted LC/MS/MS: application in sarcoma. PLoS One. 2011;6(10), e25357.
323. Nishiumi S, Kobayashi T, Ikeda A, Yoshie T, Kibi M, Izumi Y, et al. A novel serum metabolomics-based diagnostic approach for colorectal cancer. PLoS One. 2012;7(7), e40459.
324. Alix-Panabieres C, Schwarzenbach H, Pantel K. Circulating tumor cells and circulating tumor DNA. Annu Rev Med. 2012;63:199-215. doi: 10.1146/annurev-med-062310-094219.
325. Payne GS, Schmidt M, Morgan VA, Giles S, Bridges J, Ind T, et al. Evaluation of magnetic resonance diffusion and spectroscopy measurements as predictive biomarkers in stage 1 cervical cancer. Gynecol Oncol. 2010;116(2):246-52. doi: 10.1016/j.ygyno.2009.09.044.
326. Son H, Kositwattanarerk A, Hayes MP, Chuang L, Rahaman J, Heiba S, et al. PET/CT evaluation of cervical cancer: spectrum of disease. Radiographics. 2010;30(5):1251-68. doi: 10.1148/rg.305105703.
327. Herrera FG, Prior JO. The role of PET/CT in cervical cancer. Front Oncol. 2013;3:34. doi: 10.3389/fonc.2013.00034.
328. Schoder H, Gonen M. Screening for cancer with PET and PET/CT: potential and limitations. J Nucl Med. 2007;48 Suppl 1:4S-18S. doi:48/1_suppl/4S [pii].
329. Ophir J, Cespedes I, Ponnekanti H, Yazdi Y, Li X. Elastography: a quantitative method for imaging the elasticity of biological tissues. Ultrason Imaging. 1991;13(2):111-34.
330. Thomas A, Kummel S, Gemeinhardt O, Fischer T. Real-time sonoelastography of the cervix: tissue elasticity of the normal and abnormal cervix. Acad Radiol. 2007;14(2):193-200. doi: 10.1016/j.acra.2006.11.010.
331. Cebulla J, Kim E, Rhie K, Zhang J, Pathak AP. Multiscale and multi-modality visualization of angiogenesis in a human breast cancer model. Angiogenesis. 2014;17(3):695-709. doi: 10.1007/s10456-014-9429-2.
332. Kohatsu ND, Robinson JG, Torner JC. Evidence-based public health: an evolving concept. Am J Prev Med. 2004;27(5):417-21. doi: 10.1016/j.amepre.2004.07.019.
333. Franco EL, Duarte-Franco E, Rohan TE. Evidence-based policy recommendations on cancer screening and prevention. Cancer Detect Prev. 2002;26(5):350-61.
334. Townsend JS, Richardson LC, Steele CB, White DE. Evidence-based interventions and screening recommendations for colorectal cancer in comprehensive cancer control plans: a content analysis. Prev Chronic Dis. 2009;6(4):A127.
335. Davidson KG, Dubinsky TJ. Ultrasonographic evaluation of the endometrium in postmenopausal vaginal bleeding. Radiol Clin North Am. 2003;41(4):769-80.
336. Langer RD, Pierce JJ, O'Hanlan KA, Johnson SR, Espeland MA, Trabal JF, et al. Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. Postmenopausal Estrogen/Progestin Interventions Trial. N Engl J Med. 1997;337(25):1792-8. doi: 10.1056/NEJM199712183372502.
337. Remedios D, Hierath M, Ashford N, Cavanagh P, Grenier PA, Lloyd CM, et al. European survey on imaging referral guidelines. Insights Imaging. 2014;5(1):15-23. doi: 10.1007/s13244-013-0300-6.
338. Patil S, Sandberg A, Heckert E, Self W, Seal S. Protein adsorption and cellular uptake of cerium oxide nanoparticles as a function of zeta potential. Biomaterials. 2007;28(31):4600-7. doi: 10.1016/j.biomaterials.2007.07.029.
339. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010;464(7291):1067-70. doi: 10.1038/nature08956.
340. Park JY, Baek MJ, Choi ES, Woo S, Kim JH, Kim TJ, et al. Paramagnetic ultrasmall gadolinium oxide nanoparticles as advanced T1 MRI contrast agent: account for large longitudinal relaxivity, optimal particle diameter, and in vivo T1 MR images. ACS Nano. 2009;3(11):3663-9. doi: 10.1021/nn900761s.
341. Hainfeld JF, Slatkin DN, Focella TM, Smilowitz HM. Gold nanoparticles: a new X-ray contrast agent. Br J Radiol. 2006;79(939):248-53. doi: 10.1259/bjr/13169882.
342. Xing H, Bu W, Zhang S, Zheng X, Li M, Chen F, et al. Multifunctional nanoprobes for upconversion fluorescence, MR and CT trimodal imaging. Biomaterials. 2012;33(4):1079-89. doi: 10.1016/j.biomaterials.2011.10.039.
343. Basuki JS, Duong HT, Macmillan A, Erlich RB, Esser L, Akerfeldt MC, et al. Using fluorescence lifetime imaging microscopy to monitor theranostic nanoparticle uptake and intracellular doxorubicin release. ACS Nano. 2013;7(11):10175-89. doi: 10.1021/nn404407g.
344. Hu CM, Aryal S, Zhang L. Nanoparticle-assisted combination therapies for effective cancer treatment. Ther Deliv. 2010;1(2):323-34.
345. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012;63:185-98. doi: 10.1146/annurev-med-040210-162544.
346. Hu R, Wang X, Zhan X. Multi-parameter systematic strategies for predictive, preventive and personalised medicine in cancer. EPMA J. 2013;4(1):2. doi: 10.1186/1878-5085-4-2.
347. Zhan X, Desiderio DM. The use of variations in proteomes to predict, prevent, and personalize treatment for clinically nonfunctional pituitary adenomas. EPMA J. 2010;1(3):439-59. doi: 10.1007/s13167-010-0028-z.
348. Aderem A. Systems biology: its practice and challenges. Cell. 2005;121(4):511-3. doi: 10.1016/j.cell.2005.04.020.
349. Chen R, Snyder M. Promise of personalized omics to precision medicine. Wiley Interdiscip Rev Syst Biol Med. 2013;5(1):73-82. doi: 10.1002/wsbm.1198.
350. Ginsburg GS, Kuderer NM. Comparative effectiveness research, genomics-enabled personalized medicine, and rapid learning care: a common bond. J Clin Oncol. 2012;30(34):4233-42. doi: 10.1200/JCO.2012.42.6114.
351. Hood L. Systems biology: integrating technology, biology, and computation. Mech Ageing Dev. 2003;124(1):9-16. doi:10.1016/S0047-6374(02)00164-1.
352. Hood L, Tian Q. Systems approaches to biology and disease enable translational systems medicine. Genomics Proteomics Bioinformatics. 2012;10(4):181-5. doi: 10.1016/j.gpb.2012.08.004.
353. Qattan M, Demonacos C, Krstic-Demonacos M. Roadmap to personalized medicine. Croat Med J. 2012;53(4):294-7.
354. Matzke EA, O'Donoghue S, Barnes RO, Daudt H, Cheah S, Suggitt A, et al. Certification for biobanks: the program developed by the Canadian Tumour Repository Network (CTRNet). Biopreserv Biobank. 2012;10(5):426-32. doi: 10.1089/bio.2012.0026.
355. Lacroix L, Boichard A, Andre F, Soria JC. Genomes in the clinic: the Gustave Roussy Cancer Center experience. Curr Opin Genet Dev. 2014;24:99-106. doi: 10.1016/j.gde.2013.11.013.
356. Lopez-Beltran A, Vidal A, Blanca A. [Biobanking: the basis for molecular research in uro-oncology]. Arch Esp Urol. 2013;66(5):416-22.
357. Lou JJ, Mirsadraei L, Sanchez DE, Wilson RW, Shabihkhani M, Lucey GM, et al. A review of room temperature storage of biospecimen tissue and nucleic acids for anatomic pathology laboratories and biorepositories. Clin Biochem. 2014;47(4-5):267-73. doi: 10.1016/j.clinbiochem.2013.12.011.
358. Mee B, Gaffney E, Glynn SA, Donatello S, Carroll P, Connolly E, et al. Development and progress of Ireland's biobank network: Ethical, legal, and social implications (ELSI), standardized documentation, sample and data release, and international perspective. Biopreserv Biobank. 2013;11(1):3-11. doi: 10.1089/bio.2012.0028.
359. Pesch B, Bruning T, Johnen G, Casjens S, Bonberg N, Taeger D, et al. Biomarker research with prospective study designs for the early detection of cancer. Biochim Biophys Acta. 2014;1844(5):874-83. doi: 10.1016/j.bbapap.2013.12.007.
360. Wei BR, Simpson RM. Digital pathology and image analysis augment biospecimen annotation and biobank quality assurance harmonization. Clin Biochem. 2014;47(4-5):274-9. doi: 10.1016/j.clinbiochem.2013.12.008.
361. Chambers EV, Kindt AS, Semple CA. Opening sequence: computational genomics in the era of high-throughput sequencing. Genome Biol. 2011;12(12):310. doi: 10.1186/gb-2011-12-12-310.
362. Parkinson H, Sarkans U, Kolesnikov N, Abeygunawardena N, Burdett T, Dylag M, et al. ArrayExpress update-an archive of microarray and high-throughput sequencing-based functional genomics experiments. Nucleic Acids Res. 2011;39(Database issue):D1002-4. doi: 10.1093/nar/gkq1040.
363. Poon SL, McPherson JR, Tan P, Teh BT, Rozen SG. Mutation signatures of carcinogen exposure: genome-wide detection and new opportunities for cancer prevention. Genome Med. 2014;6(3):24. doi: 10.1186/gm541.
364. Ekmektzoglou KA, Samelis G, Karagiannis S, Zografos G, Xanthos T. Genomic instability in ulcerative colitis: a prerequisite for cancer in the inflammatory colon? Acta Gastroenterol Belg. 2012;75(3):293-9.
365. Giaretti W, Pentenero M, Gandolfo S, Castagnola P. Chromosomal instability, aneuploidy and routine high-resolution DNA content analysis in oral cancer risk evaluation. Future Oncol. 2012;8(10):1257-71. doi: 10.2217/fon.12.116.
366. Wakefield MJ. Genomics-from Neanderthals to high-throughput sequencing. Genome Biol. 2006;7(8):326. doi: 10.1186/gb-2006-7-8-326.
367. Evans CO, Moreno CS, Zhan X, McCabe MT, Vertino PM, Desiderio DM, et al. Molecular pathogenesis of human prolactinomas identified by gene expression profiling, RTqPCR, and proteomic analyses. Pituitary. 2008;11(3):231-45. doi: 10.1007/s11102-007-0082-2.
368. Sanchez-Pla A, Reverter F, Ruíz De Villa MC, Comabella M. Transcriptomics: mRNA and alternative splicing. J Neuroimmunol. 2012;24(1-2):23-31. doi: 10.1016/j.jneuroim.2012.04.008.
369. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005;433(7027):769-73. doi: 10.1038/nature03315.
370. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature. 2003;422(6928):198-207. doi: 10.1038/nature01511.
371. Bensimon A, Heck AJ, Aebersold R. Mass spectrometry-based proteomics and network biology. Annu Rev Biochem. 2012;81:379-405. doi: 10.1146/annurev-biochem-072909-100424.
372. Sabido E, Selevsek N, Aebersold R. Mass spectrometry-based proteomics for systems biology. Curr Opin Biotechnol. 2012;23(4):591-7. doi: 10.1016/j.copbio.2011.11.014.
373. Zhan X, Desiderio DM. Comparative proteomics analysis of human pituitary adenomas: current status and future perspectives. Mass Spectrom Rev. 2005;24(6):783-813. doi: 10.1002/mas.20039.
374. Jankova L, Chan C, Fung CL, Song X, Kwun SY, Cowley MJ, et al. Proteomic comparison of colorectal tumours and non-neoplastic mucosa from paired patient samples using iTRAQ mass spectrometry. Mol Biosyst. 2011;7(11):2997-3005. doi: 10.1039/c1mb05236e.
375. Hayakawa E, Menschaert G, De Bock PJ, Luyten W, Gevaert K, Baggerman G, et al. Improving the identification rate of endogenous peptides using electron transfer dissociation and collision-induced dissociation. J Proteome Res. 2013;12(12):5410-21. doi: 10.1021/pr400446z.
376. Sasaki K, Takahashi N, Satoh M, Yamasaki M, Minamino N. A peptidomics strategy for discovering endogenous bioactive peptides. J Proteome Res. 2010;9(10):5047-52. doi: 10.1021/pr1003455.
377. Schmidt C. Metabolomics takes its place as latest up-and-coming "omic" science. J Natl Cancer Inst. 2004;96(10):732-4.
378. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene. 2004;23(16):2934-49. doi: 10.1038/sj.onc.1207515.
379. Vadigepalli R, Chakravarthula P, Zak DE, Schwaber JS, Gonye GE. PAINT: a promoter analysis and interaction network generation tool for gene regulatory network identification. OMICS. 2003;7(3):235-52. doi: 10.1089/153623103322452378.
380. Zhou H, Chen M, Zhao D. Longitudinal MRI evaluation of intracranial development and vascular characteristics of breast cancer brain metastases in a mouse model. PLoS One. 2013;8(4), e62238. doi: 10.1371/journal.pone.0062238.
381. Khaled WT, Liu P. Cancer mouse models: past, present and future. Semin Cell Dev Biol. 2014;27:54-60. doi: 10.1016/j.semcdb.2014.04.003.
382. Haibe-Kains B, El-Hachem N, Birkbak NJ, Jin AC, Beck AH, Aerts HJ, et al. Inconsistency in large pharmacogenomic studies. Nature. 2013;504(7480):389-93. doi: 10.1038/nature12831.
383. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008;84(3):326-31. doi: 10.1038/clpt.2008.10.
384. Holmes MV, Shah T, Vickery C, Smeeth L, Hingorani AD, Casas JP. Fulfilling the promise of personalized medicine? Systematic review and field synopsis of pharmacogenetic studies. PLoS One. 2009;4(12), e7960. doi: 10.1371/journal.pone.0007960.
385. Ross S, Anand SS, Joseph P, Pare G. Promises and challenges of pharmacogenetics: an overview of study design, methodological and statistical issues. JRSM Cardiovasc Dis. 2012;1(1). doi:10.1258/cvd.2012.012001.
386. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92(4):414-7. doi: 10.1038/clpt.2012.96.
387. Golubnitschaja O, Watson ID, Topic E, Sandberg S, Ferrari M, Costigliola V. Position paper of the EPMA and EFLM: a global vision of the consolidated promotion of an integrative medical approach to advance health care. EPMA J. 2013;4(1):12. doi: 10.1186/1878-5085-4-12.
388. Golubnitschaja O, Kinkorova J, Costigliola V. Predictive, Preventive and Personalised Medicine as the hardcore of 'Horizon 2020': EPMA position paper. EPMA J. 2014;5(1):6.
389. Golubnitschaja O, Costigliola V, EPMA. General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for Predictive, Preventive and Personalised Medicine. EPMA J. 2012;3(1):14. doi:10.1186/1878-5085-3-14.
390. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer. [database on the Internet]2013. Available from: Available from: http://globocan.iarc.fr. Accessed 1 Dec 2014.
391. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132(5):1133-45. doi: 10.1002/ijc.27711.